Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + omega-3 polyunsaturated fatty acids
- Development stage
- Unknown
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy consisting of escitalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and omega-3 polyunsaturated fatty acids (PUFAs), commonly found in fish oil supplements. Escitalopram acts by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability and improving mood. Omega-3 PUFAs—primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—are thought to exert neuroprotective and anti-inflammatory effects that may enhance antidepressant efficacy. Clinical studies suggest that combining these agents can result in greater improvement of depressive symptoms compared to either agent alone[1][3][4]. This combination is being explored primarily for the treatment of depression.
- Other names
- escitalopram + omega-3 PUFAsescitalopram + fish oilescitalopram + omega-3 fatty acids
02
Targets
SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on escitalopram + omega-3 polyunsaturated fatty acids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + omega-3 polyunsaturated fatty acids.